CHD prevention rise in Scotland due to quality indicators

The introduction of the new GMS contract has improved the secondary prevention of CHD in the West of Scotland, according to Scottish research.

Researchers analysed 19,884 patients with CHD, comparing the first month of the new contract, April 2004, with the most recent data, March 2006.

They found that the proportion of patients prescribed antiplatelet therapy rose from 78 per cent to 95 per cent.

The researchers also found that for beta-blocker therapy, the proportion of patients receiving prescriptions rose from 49 per cent to 76 per cent.

What do you think? Comment below or email us at

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in